Enveric Biosciences, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. Enveric is a pre-revenue biotechnology company developing psychedelic-inspired therapeutics for mental health conditions, including lead candidate EB-002 and the EVM301 program candidate EB-003.
Financial performance and position
| Metric | Q1 2024 | Q1 2023 / prior date |
|---|---|---|
| Revenue | None reported | None reported |
| Operating expenses | $2.48 million | $4.86 million |
| Operating loss | $2.48 million | $4.86 million |
| Net loss | $2.46 million | $4.68 million |
| Net loss per share, basic and diluted | $0.61 | $2.31 |
| Operating cash used | $2.60 million | $5.14 million |
| Cash at period end | $6.36 million | $2.29 million at Dec. 31, 2023 |
| Working capital | $5.86 million | Not stated here for the prior date |
| Shareholders’ equity | $6.48 million | $1.96 million at Dec. 31, 2023 |
General and administrative expense fell 34% to $1.93 million; research and development expense fell approximately 75% to $458,155. Management attributed the reductions primarily to the 2023 workforce reduction, discontinued pursuit of the cannabinoid spin-out, lower staffing and research costs, and an Australian R&D tax incentive. No profit margin is meaningful because the company reported no revenue. The balance sheet lists no borrowing or debt balance; liabilities were primarily accounts payable and accrued liabilities.
Cash increased by $4.07 million during the quarter, mainly because $6.66 million of financing cash inflows exceeded operating cash use. Financing included proceeds from warrant exercises and the equity distribution agreement. The company issued 1.67 million shares under its at-the-market agreement and received $2.68 million from exercise of inducement warrants. Common shares outstanding were 7,294,005 at March 31 and 7,752,005 as of May 9, 2024.
Material changes, outlook and risks
- Loss narrowed year over year, with operating expenses down about 49%, but the business remains pre-revenue and continues to consume cash.
- Management states that March 31 cash is insufficient for operating needs for the 12 months following the filing. The company concludes that substantial doubt exists about its ability to continue as a going concern. Its plans include raising equity or debt, using the Lincoln Park equity line subject to conditions, seeking collaborations, and controlling spending; financing may not be available on acceptable terms or at all.
- No financial guidance or quantified operating outlook is provided. Development and clinical progress remain uncertain; EB-002’s planned Phase 1 study is supported by an Avance Clinical contract of approximately $2.22 million, with future vendor and consulting commitments of about $1.5 million in aggregate, including amounts in accounts payable.
- Key risks include clinical and regulatory uncertainty, funding needs and potential dilution, intellectual property protection, competition, ability to retain key personnel, inflation-related cost pressure, and foreign-exchange exposure. The company reports no material litigation expected by management to adversely affect its financial position.
- Nasdaq had granted an extension to May 20, 2024 to regain compliance with its minimum stockholders’ equity requirement. Enveric reported $6.48 million of equity at March 31 and believed the filing would evidence compliance, subject to Nasdaq review.
- Management reported that material weaknesses in internal control over financial reporting remained at March 31, principally related to inadequate segregation of duties. Disclosure controls and procedures were assessed as ineffective.
- After quarter-end, Enveric issued 458,000 shares on May 3 to obtain a waiver of certain variable-rate transaction restrictions and received no net proceeds from that issuance. On May 13, it issued 25,000 shares and received $21,438 gross under the Lincoln Park equity line.
Most important facts for investors to verify
- Cash runway, expected quarterly cash use, and whether subsequent financings or collaborations will provide adequate capital to address the stated going-concern uncertainty.
- Availability and terms of the Lincoln Park equity line, registration conditions, and potential share dilution.
- Nasdaq’s determination of compliance with the stockholders’ equity requirement.
- EB-002 clinical-development timing, remaining trial costs, and progress toward advancing EB-003 and other pipeline candidates.
- Remediation progress for the reported material weakness in internal controls.